medline.ch Onkologie Urologische Tumoren

	Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer. Oncol Res Yin Z, Zhen X, Li H, Duan H, Hu X, Yu T, Shi Q, Liu Z, Li Y, Zhang P, Dai P, Zhao M, Wang Z, Li C, Wang D, Tong Z. PMID: 42358824 [PubMed - in process]
	[(68)Ga]Ga-PSMA-11 PET/CT for baseline staging of high-risk prostate cancer: A real-world study. BJUI Compass Sharkey AR, Bassett P, Subesinghe M, Azad G, Aggarwal A, Hughes S, Dasgupta P, Popert R, Challacombe B, Cook GJR. PMID: 42358655 [PubMed - in process]
	Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney. Front Pediatr Yao Z, Zhanghuang C, Zhou N, Li J, Hao Z, Yan B, Zhao H. PMID: 42358575 [PubMed - in process]
	Comparison of the efficacy of different orthotopic neobladder reconstruction techniques following radical cystectomy for bladder cancer: a network meta-analysis. Front Oncol Xi Z, Ge H, Zhu J, Yang Q, Xie F, Ma X, Zhang D, Niu H, Wang Y. PMID: 42358543 [PubMed - in process]
	Early PSA Decline Predicts Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Retrospective Single-Center Study. Medicina (Kaunas) Hendem E, Koçak MZ, Y, Korkmaz M, Er MM, Araz M, Artac M, Karakurt Ery. PMID: 42356193 [PubMed - in process]
	Quality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor-Targeted Therapies: A Prospective Cross-Sectional Real-World Study. Medicina (Kaunas) Çelik S, Karatl, Atak M, Sevim HA, , Rahatl. PMID: 42356187 [PubMed - in process]
	Preoperative Psoas Muscle Index and Psoas Attenuation in Patients Undergoing Nephrectomy for Renal Cell Carcinoma: A Retrospective Cohort Study. Medicina (Kaunas) Ipek OM, Dincer E, Aydiner O, Sevinc AH, Hanci Sevinc B, Aras E. PMID: 42356167 [PubMed - in process]
	Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. J Clin Med Tohumcuo, Kö, Dü, Yeti, Mirili C, Mete B, Büyük. PMID: 42355983 [PubMed - in process]
	AIF, CK5/6, and CK20 in Bladder Urothelial Carcinoma: A Cross-Sectional Immunohistochemical Study of Grade and Stage Associations. J Clin Med Babal P, Harsanyi S, Kern S, Kuracinova KM, Krivosikova L, Trebaticky B, Ziaran S, Janegova A, Janega P. PMID: 42355861 [PubMed - in process]
	Penile Rehabilitation After Surgery for Prostate Cancer: An Umbrella Review on Traditional Approaches and Novel Perspectives. J Clin Med Seminara G, Meduri L, Leuzzi M, Antonini G, Aversa A. PMID: 42355856 [PubMed - in process]
	Association Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens. J Clin Med Fattahi S, Tuac Y, Argun O, Thomsen B, Smart AC, Chipidza FE, Leeman JE, Sayan M. PMID: 42355805 [PubMed - in process]
	Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13RÎ±2-In Vitro Study. Int J Mol Sci Klimczak A, Krawczenko A, Stamnitz S, Bielawska-Pohl A, Piotrowska P, Grzelenska H, Wypychowska A, Kisielewicz A, Mielecki M, Borowski R, Olejniczak M, Pajak-Tarnacka B. PMID: 42353280 [PubMed - in process]
	Family-Based Study Reveals PDE11A/PDE11A-AS1 Variants in Testicular Germ Cell Tumor Predisposition. Int J Mol Sci Côrtes L, Rodrigues AB, Silveira SM, Ramírez-Mejía JM, Dreyer CS, Aagaard MM, Fernandez GJ, Lopes A, Filho JCST, Rogatto SR. PMID: 42352980 [PubMed - in process]
	AQP1 Suppresses Clear Cell Renal Cell Carcinoma via Epigenetic Silencing and TNF-Mediated Apoptosis. Int J Mol Sci Pang S, Bi Y, Liu Y, Wang S, Yi B, Zhu L, Wang J. PMID: 42352939 [PubMed - in process]
	Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment. Int J Mol Sci Baek SW, Yoon SY, Kim SK, Leem SH. PMID: 42352877 [PubMed - in process]
	Regulated Cell Death in Prostate Cancer: Immunometabolic Crosstalk, Therapeutic Resistance, and Biomarker-Guided Combination Strategies. Cancers (Basel) Wang C, Li N. PMID: 42352546 [PubMed - in process]
	Cytokine-STAT3 Signaling Axis in Clear Cell Renal Cell Carcinoma: Implications for Tumor Microenvironment and Biomarker Discovery. Cancers (Basel) , Dohál M, Gondá, Ma, , Cipková L, Fra, . PMID: 42352504 [PubMed - in process]
	Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI-PARP-Radioligand Era. Cancers (Basel) Somoto T, Utsumi T, Ikeda R, Sugimoto T, Ishitsuka N, Kadono Y, Noro T, Suzuki Y, Iijima S, Sugizaki Y, Oka R, Endo T, Kamiya N, Suzuki H. PMID: 42352498 [PubMed - in process]
	Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004-2022). Cancers (Basel) Pustake M, Railkar A, Ongsyping S, Joshi S, Ogedegbe O, Ganiyani MA, Gaur S, Gomez J, Garje R. PMID: 42352495 [PubMed - in process]
	Association Between Metabolic Syndrome and Prostate Cancer: A Systematic Review. Cancers (Basel) Peshin S, Takrori E, Lal BM, Singal S, Arnaoutakis K, Kunthur A, Tu SM. PMID: 42352487 [PubMed - in process]

Artikel 1 - 20 / 179257

Seite 1 von 8963

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung